Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia
2020 · JAMA Oncology · 342 citations
https://doi.org/10.1001/jamaoncol.2020.4600
N
Nicholas J. Short
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.0K
Papers
16.8K
Citations
64
h-index
301
i10-index
Nicholas J. Short is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Acute Lymphoblastic Leukemia research. The author has an h-index of 64, co-authored 892 publications.
ORCID: 0000-0002-2983-2738Papers by this author
worksInotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
2018 · The Lancet Oncology · 238 citations
https://doi.org/10.1016/s1470-2045(18)30011-1
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
2023 · Journal of Hematology & Oncology · 105 citations
https://doi.org/10.1186/s13045-023-01409-5
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
2021 · Blood Cancer Journal · 94 citations
https://doi.org/10.1038/s41408-021-00557-6
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
2022 · Blood Cancer Journal · 92 citations
https://doi.org/10.1038/s41408-021-00604-2
Current status and research directions in acute myeloid leukemia
2024 · Blood Cancer Journal · 89 citations
https://doi.org/10.1038/s41408-024-01143-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat